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LHRH and its analogues produce profound antireproductive effects in both sexes of a vari-
ety of animal species. Although the LHRH agonists induce gonadotropin release, gonadal
steroid secretion, ovulation, and spermatogenesis as an expression of their traditional profer-
tility pharmacologic profile, they paradoxically and characteristically cause predominant an-
tifertility effects which have been extensively evaluated for potential contraceptive purposes.
These agonists produce their antireproductive effects in both males and females by common
mechanisms, ultimately resulting in disruption of pituitary-gonadal function, depression of
steroidogenesis, and inhibition of target organs dependent on such gonadal support. Similar
antireproductive effects have been observed with the LHRH antagonists which competitively
inhibit LHRH-induced gonadotropin secretion resulting in reduced blood gonadal steroid
levels. Use ofthe inhibitory properties has been extended to cancer therapy based on theability
of the LHRH analogues (particularly the agonists) to inhibit the growth of steroid-dependent
(responsive) tumors (e.g., mammary, prostate) similar to that produced by gonadectomy and
antisteroid treatments. The use of these peptides for selected hormone-sensitive tumors
presents a novel pharmacotherapeutic application for this class of drug.
INTRODUCTION
The extensive pharmacologic evaluation of luteinizing hormone releasing hor-
mone (LHRH) and its numerous analogues (agonists and antagonists) has clearly
established the antireproductive properties of this class of compound [1-5]. The
paradoxical antifertility activity and high potency of the agonists, in particular, are
well-documented and have provided the basis for a new contraceptive approach in
both females and males. However, it is only within the last few years that quantities
of antagonists with sufficient potency have become available to permit their more
detailed pharmacologic evaluation. A general scheme showing these relationships is
presented in Fig. 1.
LHRH and its more potent congeners ("super" agonists) possess the traditional
profertility property of inducing pituitary follicle stimulating hormone (FSH) and
luteinizing hormone (LH) release, which are, in turn, responsible for ovulation,
spermatogenesis, and gonadal steroid secretion. However, using various dosing
regimens and routes of administration in animal experiments and in clinical trials,
these peptides invariably produced paradoxical antireproductive effects. This ap-
parent contradictory but predictable contraceptive activity has been repeatedly
demonstrated in a wide variety of studies [1-5]. Numerous synthetic analogues that
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FIG. 1. LHRH analogues in fertility regulation.
have become available since LHRH was isolated, identified, and synthesized in
1971, have been used to demonstrate that the traditional agonist properties are
characteristically correlated with and predictable of their antifertility effects. The
ability ofthese compounds to inhibit or impede ovarian and testicular steroidogene-
sis, and consequently produce regression of the reproductive structures dependent
on such steroid support, led to the concept that gonadal steroid-dependent (respon-
sive) tumors might also be affected in a manner analogous to that produced by
gonadectomy or by antiandrogenic or antiestrogenic drugs.
This review will describe, for the most part, the basic principles and developments
supporting the paradoxical antireproductive effects of the LHRH agonists, current
concepts regarding the mechanisms that are involved and the application of these
properties as potential therapeutic antitumor agents. A brief reference will be made
to the LHRH antagonists which also possess antireproductive properties but have
been demonstrated only recently to produce antitumor effects.
LHRH AGONISTS PROPERTIES: TRADITIONAL AND PARADOXICAL
ANTIFERTILITY EFFECTS
LHRH and its agonistic derivatives stimulate the pituitary-gonadal target organ
axis under physiological and carefully regimented pharmacologic conditions in
females and males.
In contrast, numerous studies [1] have demonstrated that the parent molecule,
LHRH, was capable of terminating pregnancy when administered to inseminated
rats either preimplantationally (claudogen test, days 1-7) or postimplantationally
(interceptive test, days 7-12). This paradoxical antifertility effect gained prominence
when it was demonstrated that several synthetic congeners produced similar effects
at considerably lower doses. Subsequently, it was established that such antirepro-
ductive consequences were consistently associated with the ability of this class of
peptide to release LH (and induce ovulation); these basic profertility effects served
to identify and predict those LHRH agonists with contragestational (and eventually
broad antireproductive) activity and enhanced potency. The amino acid sequence of
LHRH and representative structural modifications that were made to yield some of
the more potent agonists are shown in Fig. 2. The various agonists receiving signifi-
cant attention and their dual properties (ovulation induction and postcoital con-
traception) from studies in the rat are listed in Table 1. Table 2 describes the general
reproductive pharmacologic profile of the LHRH agonists, including mechanisms of
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FIG. 2. Structure of LH-RH and exemplary agonists.
action, that have been reported in the animal and clinical literature. As noted in
Table 2, these agents can also produce extra-pituitary effects, adding another dimen-
sion to their proposed mechanism(s) of action. Table 3 illustrates the laboratory
observations with the Wyeth compound, Wy-40,972, which possesses a reproductive
and safety profile characteristic of the LHRH agonist class.
The LHRH agonists, by impeding gonadal steroidogenesis, produce regression of
TABLE 1
The Agonist and Post-Coital Contraceptive Profile of the [D-Ala6]-LH-RH and [D-Trp9]-LH-RH Series
COMPOUND AGONIST POST-COITAL CONTRACEPTION
OVULATION INDUCTION CLAUDOGEN INTERCEPTIVE
MED1000, pg/RAT. I.V. LMEDioo, pg/RAT/DAY, S.C.]I
LH-RH 5.0 200-300 200 -500
D-AIa6-LH-RH 1.0 10 100
D-AIa6-Des-GIyI0-Pro9-NHEt-LH-RH 1.0 1.0 25-50
D-Aa6-Na-Me-Leu7-Des-Glylo-Pro9-NHEt-LH-RH 0.10 1.0 1.0
D-Trp6-LH-RH 0.10 10 1.0-10
D-Trp6-Des-GIyI0-Pro9-NHEt-LH-RH 0.10 1.0 10
D-Trp6-Nc-Me-Leu7-Des-GIYIO-Pro9-NHEt-LH-RH| 0.10 1.0 - 1.0
D-Ser(TBU)6-Des-Glyo_Pro9-NHEt-LH-RH 0.10 - 1.0 10 10
(BuserelinI
* Approximate minimal effective 100% dose
NHEt = ethylamide
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Reproductive Pharmacologic Profile of LHRH Agonists
1. TRADITIONAL EFFECTS
a) STIMULATE GONADOTROPIN SECRETION
b) INDUCE OVULATION
c) INDUCE SPERMATOGENESIS
d) INDUCE STEROIDOGENESIS
2. PARADOXICAL ANTI-FERTILITY EFFECTS
a) HYPERSECRETION OF PITUITARY LH AND FSH
b) PITUITARY DESENSITIZATION WITH CHRONIC TREATMENT (DECREASED RESPONSIVENESS)
c) PREMATURE OVULATION; INHIBITION OF OVULATION
d) LUTEOLYSIS
e) DOWNREGULATION OF GONADAL GONADOTROPIN RECEPTORS (DECREASED RECEPTOR NUMBERS)
f) INTERFERENCE WITH GONADAL STEROIDOGENESIS - ACT EITHER DIRECTLY OR VIA LH
RELEASE TO EFFECT ENZYMES IN STEROIDOGENIC PATHWA,Y (INHIBITION OF 17-HYDROXYLASES
AND 17-DESMOLASES; STIMULATION OF REDUCTASES AND AROMATASES)
g) TERMINATE PREGNANCY
h) DISRUPT ESTROUS CYCLE; CAUSE OVARIAN AND UTERINE REGRESSION AND REDUCED
FECUNDITY
i) SHORTEN MENSTRUAL CYCLE; EARLY MENSTRUAL ONSET; AMENORRHEA
j) PUBERTAL RETARDATION; INHIBITION OF PRECOCIOUS PUBERTY
') INHIBIT MALE REPRODUCTION - ANTISPERMATOGENIC; NHI B T TESTOSTERONE PRODUCT ON,
MATING BEHAVIOR AND SECONDARY REPRODUCTIVE ORGANS
I) 'RODUCE EXTRAPITUITARY EFFECTS (IN ABSENCE OF HYPOPHYSIS) DIRECTLY AT LEVEL OF GONADS,
'ECONDARY REPRODUCTIVE TARGET TISSUES AND UTERUS/PLACENTA; PREGNANCY TERMINATION
I HYPOPHYSECTOMIZED ANIMAL
TABLE 3
Profile of Wy-40,972
A. AS AN AGONIST
1. POTENT LHRH AGONIST AS DETERMINED BY GONADOTROPIN RELEASE AND OVULATION INDUCTION
2. EFFECTIVE BY 12 ROUTES OF ADMINISTRATION
B. AS AN ANTIFERTILITY AGENT
1. TERMlINATES PREGNANCY PRE AND POST IMPLANTATIONALLY BY 6 ROUTES OF ADMINISTRATION
2. INDUCES LUTEOLYS IS
3. INHIBITS OVULATION; INTERFERES WITH STEROIDOGENESIS
4. DISRUPTS ESTROUS CYCLE
5. INHIBITS FEMALE PUBERTY
6. INHIBITS SPERMATOGENES IS AND ANDROGEN SECRETION
C. SAFETY
1. NO UNTOWARD SIDE EFFECTS AT MULTIPLES OF EFFICACIOUS DOSES UNDER CHRONIC REGIMENS
2. NO EFFECTS ON NON-REPRODUCTIVE SYSTEMS
3. WIDE THERAPEUTIC/SAFETY MARGIN
4. NO TERATOGENIC LIABILITY
5. ANTIFERTILITY EFFECTS ARE REVERSIBLE WITH RAPID RETURN TO NORMAl FERTILE STATES
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steroid-supported reproductive tissues in both females and males. The sequelae of
events and the proposed disruption of the steroidogenic pathway are visualized in
Figs. 3 and 4, respectively. The entire antireproductive spectrum ofeffects is reversi-
ble, with the time course of recovery following cessation of treatment dependent
upon the dose and the length ofits administration. This aspect represents an impor-
tant variable in designing dosing protocols to ensure significant tumor regression
and to prevent its recrudescence should LHRH agonist treatment be withdrawn; this
matter will be discussed more fully in a subsequent section.
Many ofthe aforementioned agonists are undergoing extensive clinical evaluation
as contraceptives. The LH-releasing dose in humans of several of these compounds
with various routes of administration are listed in Table 4. The contraceptive doses
employed are generally multiples of the single LH-releasing dose which eventually
lead to downregulation of gonadal gonadotropin receptors, impedance of steroido-
genesis, and disruption of conceptive patterns. Table 5 summarizes the broader
clinical applications of LHRH and analogues (both the agonists and the antag-
onists) that include their utility as diagnostic, therapeutic, and contraceptive agents.
With regard to the LHRH antagonists, these particular derivatives of LHRH com-
petively inhibit the release of pituitary gonadotropins at the hypophysial level and
also have been shown to act at a hypothalamic site, inhibiting the secretion of en-
dogenous LHRH. Although it is only recently that antagonists of sufficient activ-
ity, potency, and quantity have become available for animal and clinical investiga-
tion, they are mentioned since they too can result in several of the effects observed
with the agonists.
Interestingly, because the LHRH agonists (as well as the antagonists) can produce
antireproductive effects through gonadotropic/steroidogenic hindrance, many
disease processes that are dependent on these hormones for their support (e.g., hir-
sutism, precocious puberty, acne, endometriosis) become potential candidates for
LHRH analogue therapy (Fig. 5).
ANTITUMOR EFFECTS OF LHRH ANALOGUES-ANIMAL STUDIES
Agonists
The marked inhibitory influences of the agonists on gonadal steroid-producing
and gonadal steroid-dependent tissues led to consideration of their therapeutic util-
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FIG. 3. Antireproductive effects of LHRH agonists.
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FIG. 4. Proposed LHRH agonist-induced gonadal inhibition: effect on the steroidogenic pathway.
ity as antitumor agents in a manner akin to that produced by antiestrogenic (e.g.,
Tamoxifen) [6] and antiandrogenic (e.g., Cyproterone acetate) [7] drugs or by
gonadectomy. Several of the compounds (and their sponsors) that are being in-
vestigated both in animal tumor models and in clinical settings include: D-Trp6-
LHRH (Schally); D-Trp6-DesGly10-Pro9-NHEt-LHRH (Salk Institute); D-Trp6-Nc
MeLeu'-DesGly'0-Pro9-NHEt-LHRH (Wyeth Labs., Wy-40,972); D-Leu6-DesGly10-
Pro9-NHEt-LHRH [Leuprolide; A43818 (Abbott Labs./Takeda Pharmaceuticals)];
D-Ser(TBU)6-AzGlyt0-LHRH (ICI Ltd., ICI118630); D-Ala6-DesGlyt0-Pro9-NHEt-
LHRH (Schally); D-Ser(TBU)6-DesGly10-Pro9-NHEt-LHRH [Buserelin; HOE 766
(Hoechst AG)].
a. Female Reproductive Tumors In 1976, reports by Johnson et al. [8] and De
Sombre et al. [9] initially demonstrated that the LHRH agonist, Leuprolide, could
cause the regression of a spontaneous mammary tumor or mammary tumors
induced in rats by 7,12-dimethylbenz(a)anthracene (DMBA). During continuous
treatment (about six weeks of daily subcutaneous administration) approximately 80ANTITUMOR EFFECTS OF LHRH ANALOGUES-A REVIEW
TABLE 4
Effect of LH-RH and Agonists on LH Release in Humans by Various Routes of Administration
COMPOUND SC IM PO NASAL VAGINAL RECTAL
L- LH-RELEASING DOSE, pg/PERSON (SingleRx)
500;
LH-RH 'GONADORELIN) 100-250 25 -- 1200-1300
DesGlyl0-Pro9-NHEt-LHRH 100 -- -- -- -- --
D-Leu6-DesGlyl0-Pro9-NHEt-LH-RHILEUPROLIDE) 5-25 5-10 10, 000 100 2000 2000
D-Trp6-DesGIy'0-Pro9-NHEt-LH-RH 10 10 -- 50;..500 -- --
D-Ser(TBU)6-DesGlyl0-Pro9-NHEt-LH-RH 5 10 -- >200<400 --
(Buserelin) 10-100
D-Trp6-LH-RH 10 10 -- 500 -- --
D-AIa6-DesGly10-Pro9-NHEt-LH-RH -- 150 -- 500 -- --
D-Phe6-DesGIylOPro9-NHEt-LH-RH -- -- -- 500 -- --
D-Trp6--DesGlyl-NcMeLeu7-Pro9-NHEt-LH-RH - 10 -- --
(WY-40972)
percent ofthe DMBA tumors regressed and, ofthese, 50 percent disappeared. With-
drawal ofanalogue for a period of four weeks led to tumor regrowth and to the ap-
pearance of new tumors. The antitumor effect of the peptide was equivalent to that
of ovariectomy, suggesting that support of the tumor was estrogen-dependent.
The studies by Nicholson and colleagues [10-12) and Lamberts et al. [13] in the rat
showed that the agonist, D-Ser(TBU)6-AzGly10-LHRH, also was capable ofcausing
regression ofDMBA-induced mammary tumors and ofestrogen-induced transplant-
able prolactin (PRL)-secreting rat pituitary tumors (7315A), respectively. In these
TABLE 5
Clinical Uses of LHRH and Analogues
1. DIAGNOSTIC
A) EVALUATION OF INTEGRITY OF HYPOTHALAMIC-HYPOPHYSIAL-GONADAL AXIS
IN REPRODUCTIVE HYPOFUNCTION WITH AGONISTS.
B) PHARMACOLOGIC IDENTIFICATION: POTENCY AND ACTIVITY IDENTIFICATION
IN NORMAL SUBJECTS WITH AGONISTS AND ANTAGONISTS.
2. THERAPEUTIC (UNDER INVESTIGATION)
STIMULATION OF REPRODUCTIVE FUNCTION WITH AGONISTS IN CLINICAL
CONDITIONS SUCH AS AMENORRHEA, ANOVULATION, HYPOGONADISM, RETARDED
PUBERTY, NON-DESCENDED TESTES, ETC.; USE OF AGONISTS AND ANTAGONISTS IN
PRECOCIOUS PUBERTY; USE OF AGONISTS AND ANTAGONISTS IN GONADAL STEROID-
DEPENDENT TUMORS; ENDOMETRIOSIS; HIRSUTISM;
ACNE; CYSTIC OVARIAN DISEASE.
3. CONTRACEPTIVE (UNDER INVESTIGATION)
A) INHIBITION OF OVULATION AND OF PREGNANCY WITH LH-RH ANTAGONISTS.
B) INHIBITION OF OVULATION; LUTEOLYSIS, PREGNANCY TERMINATION WITH
LHRH AGONISTS.
C) INHIBITION OF SPERMATOGENESIS WITH LHRH AGONISTS AND ANTAGONISTS.
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FIG. 5. Potential clinical applica-
tions ofthe antireproductive effects of
LHRH analogues.
studies, the tumor-inhibiting effects ofthe compound were associated with ageneral
reduction in blood levels of estradiol and prolactin; overall, the antitumor results
were similar to those observed with Tamoxifen treatment or ovariectomy.
Corbin et al. [14] reported that the development of tumors in four-day-old
hamsters inoculated with virulent mouse mammary tumor(MMT) cells was impeded
by parenteral administration of either LHRH or D-Ala6-DesGly10-Pro9-NHEt-
LHRH (Wy-18,481) for a period of ten days (Fig. 6). Tumor size remained de-
pressed during the five days following cessation of treatment. It is noteworthy that
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FIG. 6. Effect of LHRH or agonist on mouse mammary tumor (MMT) growth in
neonatal hamsters (with permission from Raven Press, New York, 1980 [141).
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this tumor retardation occurred during suppression of the animal's own immune
defense system, since these recipients were treated with antilymphocytic serum
(ALS) on two occasions during the study. Thus, the peptides attenuated tumor
growth under conditions which tended to promote maximal tumor growth. Kelly et
al. [15] and Turcot-Lemay et al. [ISa], utilizing the same LHRH agonist chronically,
demonstrated similar effects on DMBA-induced tumors in rats, associated with
significant increases in blood levels of LH and FSH, and a dramatic decline in pro-
gesterone and prolactin levels. These investigators suggested that LHRH agonists
produce a "functional" castration, such effects being consistent with antifertility ef-
fects observed by others.
These collective results reinforce the concept that the reduction of the number of
tumors and the tumor regression produced by chronic treatment with these peptides
is analogous to that observed following ovariectomy or treatment with the an-
tiestrogen, Tamoxifen [8-10]; furthermore, cessation of peptide treatment can lead
to a recrudescence of the tumor, which upon reinitiation of treatment, once again is
followed by tumor regression [9]. These data underline the requirement for uninter-
rupted or chronic intermittent administration of these compounds.
The predominant mechanism by which pharmacologic and sustained doses of
LHRH and agonists produce their antireproductive manifestations is via initial
hypersecretion of pituitary LH and subsequent downregulation ofgonadal receptors
for LH, FSH, and PRL (decreased receptor numbers), eventually followed, with
chronic administration, by pituitary desensitization and overall inhibition of
gonadal steroidogenesis. In contrast, the antisteroidal drugs (e.g., Tamoxifen,
(Cyproterone acetate) can act by blocking the effect ofendogenous gonadal steroids
directly at the target organ receptor, interfering with thecytoplasmic/nuclear steroid
expression at the cellular level [6,7]. Thus, while the mechanisms of action of the
LHRH agonists and those of the classical antiestrogens and antiandrogens are dif-
ferent, the end result is the same: interruption of steroid support for the tumor.
Additionally, there are data supporting extrapituitary, direct gonadal or direct
gonadal target organ effects of these peptides [16]. In view of the possibility that
LHRH agonists also may act directly on the tumor, we performed a dose-response
study in which mouse mammary tumor cells were subjected, in vitro, to Wy-40,972
for seven days. The results (unpublished), described in Fig. 7, reveal a tendency
toward a dose-related retardation in the increase of the viable cell population.
However, after the fourth day of treatment, in spite of continuing exposure to the
peptide, the number ofviable cells reaches control levels. Because these cells grow so
rapidly, relatively high doses of the agonist were required. The rapid growth pattern
is further observed beyond the seventh day; a growth plateau eventually is reached
followed by a rapid decline in the viable population and ensuing morbidity as the
cells simply exhaust their limited environment. These preliminary results suggest the
possibility of a direct effect of the agonist on the tumor.
In the studies reported by Rose and Pruitt [17,18] the LHRH agonist, Leuprolide,
caused regression of rat mammary tumors induced by DMBA or by N-nitrosome-
thylurea (NMU); such tumors also responded favorably to ovariectomy or Tamox-
ifen treatment. Similar results were obtained by Danguy et al. [19] who also utilized
Leuprolide in DMBA-induced tumor-bearing rats. In addition, these investigators
showed that six weeks of treatment not only produced mammary tumor regression
but also atrophy of pituitary lactotropes and decreases serum prolactin concentra-
tions, the latter effect having been observed by several of the other investigators.
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FIG. 7. Effect of LHRH agonist (Wy-40,972) on in vitro growth of MMT cells.
It is clear that treatment with several of the LHRH agonists produce their
palliative effects on several types of experimentally induced tumors by minimizing
or removing the supportive effect of estrogen, thereby mimicking the effects ob-
tained with ovariectomy or antiestrogen therapy.
The role of prolactin in supporting mammary tumor growth and its modification
by the agonists is an important point of consideration. Prolactin may have a direct
effect on the tumor itself or act through its ability to increase estrogen receptor con-
tent or stimulate estrogen secretion. Thus, prolactin may play a permissive role in
mammary tumor growth and that it is the estrogen (and perhaps other ovarian
steroids) upon which the tumor depends. Furthermore, the degree to which prolactin
plays a promotional or supportive role may be a function of the nature of the mam-
mary tumor itself. The results of Danguy et al. [19] showed that while Leuprolide
produced a greater suppression of serum prolactin levels than did ovariectomy, the
peptide was less effective than ovariectomy in suppressing tumor growth. With
regard to the Rose and Pruitt studies [17,18] the anti-DMBA-induced tumor effect
of Leuprolide was impeded when estradiol benzoate was administered concomi-
tantly. Moreover, when perphenazine (a phenothiazine which produces hyperprolac-
tinemia) also was administered with Leuprolide, the antitumor efficacy of the latter
likewise was impaired. It was suggested that the peptide produced its antitumor ef-
fect through initial inhibition of ovarian steroidogenesis with consequential hypo-
prolactinemia. In contrast, while Leuprolide caused regression of rat tumors in-
duced by NMU, its effectiveness was inhibited by estradiol benzoate but not by per-
phenazine [18]. These investigators suggested that NMU-induced tumors are
estrogen rather than prolactin-dependent, with the analogue producing a phar-
macologic ovariectomy; additionally, they proposed that NMU-induced mammary
tumors reflect the clinical disease state which is not responsive to prolactin inhibitors
such as 2-Br-a-ergocryptine [20].
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It is difficult to discern the degree to which estrogen or prolactin contributes to
mammary tumor genesis and maintenance. DMBA-induced mammary tumors ob-
viously are hormone-dependent and will regress following ovariectomy or hypophy-
sectomy [21]. Kelly et al. [15] and Turcot-Lemay et al. [15a] showed that the LHRH
agonist, D-Ala'-DesG1y10-Pro9-NHEt-LHRH, lowered the tumor concentrations of
progesterone and prolactin receptors during the course of DMBA-mammary tumor
growth retardation of intact rats; estradiol receptor levels were unaltered. However,
ovariectomy alone was shown to lower the number of estradiol receptors in the
tumor as well as those for progesterone and prolactin. Tsai et al. [22] also demon-
strated that ovariectomy of rats bearing DMBA tumors produces a conspicuous loss
ofprolactin receptors within the regressing tumor. While both estradiol and prolac-
tin influence DMBA tumor growth, prolactin appears to play the predominant role,
since prolactin can, and estradiol cannot, induce tumor regrowth following regres-
sion due to hypophysectomy of DMBA-tumor bearing animals. The report of
Arafah et al. [23] using hypophysectomized, hormone-replaced, DMBA-tumor rats
concludes that prolactin is the major hormone precipitating the growth of this par-
ticular tumor. Such tumors are rich in prolactin, estradiol, and progesterone recep-
tors; estrogen receptor levels decline following ovariectomy or treatment with
legotrile mesylate, an inhibitor ofprolactin secretion, and the estrogen receptors are
restored in the tumorfollowing either estradiol orprolactin administration. Further-
more, the reduced progesterone receptor levels within the tumor following ovariec-
tomy return to control values with estradiol replacement, but not with prolactin;
ovariectomy also lowers tumor prolactin receptor levels which are replenished by
estradiol replacement but not with prolactin. These hormonal/receptor interactions
are extremely complex and confound the choice of therapy where antihormone
treatment might be appropriate based on tumor receptor analysis. It would appear
though that tumors bearing gonadal-steroid receptors and/or prolactin receptors are
the ones that are most amenable to antihormone intervention; however, the role of
growth hormone must not be overlooked. For a more detailed coverage of these
issues, the reader is referred to the publications of Arafah and others [23-31c]
b. Male Reproductive Tumors Numerous reports have demonstrated the an-
tireproductive properties of LHRH and its agonists in the male [1,4,32-35]. The
LHRH agonists have been shown to inhibit, gravimetrically, histologically, hor-
monally, germinally, and behaviorally, the reproductive status of the male, in-
cluding humans [36].
Chronic administration of LHRH oragonists produce a loss of testicular LH and
prolactin receptors, decreased androgen synthesis and blood levels, a reduction in
the weight of the testes, testicular histologic disorganization, inhibition of sper-
matogenesis, and reduced weights of the sexual accessory apparatus[32,37]. Thus,
the eventual decrease in androgen secretion observed in LHRH-agonist-treated ani-
mals provided the basis for the potential use of these peptides, either alone or as an
adjunct to other therapies, in androgen-dependent pathologies in the human male.
Redding and Schally[38,39] evaluated the effect of D-Trp6-LHRH on the devel-
opment oftwo different types oftransplantable prostatic tumors in young male rats:
(1) the Segaloff squamous cell tumor 11095 which can be induced by implanting
methylcholanthrene into the ventral prostate, and (2) the spontaneous Dunning
adenocarcinoma R3327. The former tumor is partially hormone-dependent and is
influenced by castration or by estrogenic or progestational treatment; the latter is
believed to represent the human model, requiring androgens for its maintenance.
Chronic treatment with the analogue for a period of 14-42 days produced qual-
37itatively similar effects in both animal models. Predictably, the agonist significantly
lowered serum levels of LH, prolactin, and testosterone, associated with reduction
in the weights of the testes and ventral prostate. Serum progesterone levels were in-
creased, as described by others [40,41]. Prostatic tumor weights were significantly
decreased. With respect to the Dunning tumor, tumor volume was drastically
diminished during exposure to the compound; the percentage increase in tumor
volume was severely retarded as well as a lengthening of cell doubling time when
compared to untreated control tumors.
Antagonists
The preceding studies have dealt exclusively with the antitumor effects of the
LHRH agonists. There are only a few studies relating to the antitumor effects of the
antagonists. A recent report by Redding et al. [42] has demonstrated that newly
developed potent LHRH antagonists likewise are capable ofdecreasing tumor size in
animals. Historically, the LHRH antagonists required considerably greater chemical
modification than the agonists to produce a series ofpotent molecules that would ef-
fectively compete with LHRH at the level of the pituitary receptor, thereby blocking
the ability of LHRH to stimulate the secretion of LH and FSH. In animals and in
limited human trials, the reproductive consequences of LHRH antagonist ad-
ministration include inhibition of gonadotropin secretion, ovulation, and of
pregnancy, disruption of testicular and accessory reproductive organ function and
of gonadal steroid production [3,43].
Redding et al. [42] administered the LHRH antagonists, NAc-pF-D-Phe', pCl-D-
Phe2-D-Trp36, D-Alal°-LHRH, and NAc-pCl-D-Phe"2, D-Trp3, D-Phe6, D-Alal°-
LHRH, to rats bearing either the Segaloff squamous cell or the Dunning adenocar-
cinoma of the prostate. A daily subcutaneous dose of 50 atg/rat from 17-42 days
produced the following overall effects: decreased weight of the whole prostate;
depressed serum levels of LH, FSH, prolactin, and testosterone; increased serum
progesterone levels; no effect on the weights of the anterior pituitary gland, testes,
and adrenals.
Preliminary results from our laboratory (unpublished) reinforce the antitumor ef-
fect of the LHRH antagonists. Neonatal hamsters were inoculated with MMT cells
(and ALS) as previously described [14] and intermittently treated parenterally with
the LHRH antagonist, AC-dehydroPro1-pF-D-Phe2-D-Trp3'6-LHRH (Wy-44,599;
obtained from the Salk Institute), over a period of ten days. The data in Fig. 8 reveal
a dose-related retardation of tumor volume growth.
The available data suggest that both the LHRH agonists and the antagonists can
inhibit the growth of androgen- and estrogen-dependent tumors by their ability,
although by different mechanisms, to significantly depress gonadal steroidogenic
function and perhaps, by an additional effect (ofthe agonist), directly on the tumor.
ANTITUMOR EFFECTS OF LHRH AGONISTS-CLINICAL STUDIES
It is only recently that data have appeared in the clinical literature on the potential
efficacy of the LHRH agonists as a tumor therapy. These studies represent an
outgrowth from the earlier animal and human contraceptive investigations and more
recent work in animal tumor models [1-5,32-37,44-46].
A preliminary study was carried out by Faure et al. [47,48] using either daily sub-
cutaneous (50 ,tg for one to six months) or daily intranasal (200 and 500Itg for three
to eight months) administration of Buserelin to patients with prostatic cancer. In-
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FIG. 8. Effect of LHRH antagonist (Wy-44,599) on mouse mammary tumor (MMT) growth
in neonatal hamsters.
hibition of pituitary-gonadal function was observed: inhibition of LH respon-
siveness and decreased levels of serum testosterone and 170H-progesterone. The
decrease in these latter steroids was associated with no change in pregnenolone and
progesterone, indicating that inhibition of androgen synthesis was due to blockade
of 17-hydroxylase activity. Superficial physical examination of the patients sug-
gested a reduction in tumor mass.
The utility of "medical castration" for treating endocrine-dependent neoplasias
also has been explored by Tolis et al. [49,50], Harvey et al. [51], and Warner et al.
L52-541 using Leuprolide and D-Trpl-LHRH in patients with prostatic carcinoma or
breast cancer. In the preliminary Tolis study [491, daily subcutaneous administration
of 1,000 fig of the former compound, or 50-100 Itg of the latter, to males for 6-20
weeks, produced the predictable declines in LH, FSH, testosterone, dihydrotes-
tosterone, and in estrone and estradiol. Decrease ofprostatic mass and improvement
of urinary outflow obstruction were documented. In the more detailed report Tolis
et al. [50] treated ten geriatric patients with prostatic carcinoma (four with severe in-
capacitation due to pain; two with disseminated osteoblastic metastases; two with
urinary flow obstruction) with either D-Trp6-LHRH (100 A4g/day, subcutaneously)
or Buserelin (50 itg/day, subcutaneously or 500 ,^4g twice daily) for six weeks to 12
months. In general, patients experienced significant clinical improvement. In addi-
tion to achieving a "medical castration" (significant suppression of blood levels of
testosterone and estradiol) there was relief of pain, decline in acid and alkaline
phosphatase levels, improvement of urinary outflow obstruction and bone lesions
(evidenced by isotopic bone imaging), and reduced prostatic mass (documented by
ultrasonography). There results, although derived from a very small population, are
encouraging for they indicate the potential use of the LHRH agonists in
ameliorating the progress of a disabling prostatic malignancy.
Harvey et al. [51] and Warner and associates [52-54] carried out a series ofstudies
39with Leuprolide on patients with postmenopausal advanced breast cancer or pro-
static carcinoma. The 31 female subjects, most of whom had received prior therapy
for metastatic mammary carcinoma and who were either estrogen receptor positive
(ER+) or antihormone responsive, were administered a daily subcutaneous dose of
1.0 to 5.0 mg of the agonist for up to 30 weeks. Heterogeneous effects were ob-
tained: 16 percent showed objective responses; 19 percent were stabilized, and 65
percent had disease progression. Remissions in the responder group lasted from 12
to 30 weeks. No side effects of the drug were obvious; however, it was not known
what role the initial therapy played in influencing the outcome of the trial with the
agonist.
In the male investigation, 57 patients with prostatic cancer were administered the
analogue (1.0-10 mg/day, subcutaneously) for eleven weeks. An initial study in the
androgen-dependent rat prostate tumor model (Noble adenocarcinoma) [55]
demonstrated that chronic administration of the agonist produced decreased size of
the prostate, seminal vesicle, and testes; reduction of blood levels of LH, FSH, and
testosterone; inhibition of 17a-hydroxylase and C-17,20 lyase activity; induction of
5a-reductase and 3-keto-reductase activity and direct inhibition of testicular LH
receptor numbers. The authors reported that the clinical data paralleled those de-
rived from the animal study: gonadotropin levels were markedly suppressed and tes-
tosterone decreased to levels comparable to those found in the 31 castrate control
subjects with prostate tumors. Additionally, dihydrotestosterone and 3a-andro-
stanediol values were reduced and objective tumor regression was observed. Based
on these clinical results and the analogous antiandrogenic/antitumor effects in the
animal model, these investigators emphasized the value ofprimary treatment ofpro-
static carcinoma employing the "medical castration" effect ofthe agonist as an alter-
native to surgical orchiectomy [54].
A generalized scheme of the possible mechanisms of action of LHRH agonists on
tumor regression is depicted in Fig. 9.
LHRH AGONIST
EXHAUSTION ITARY
r
VIA CHRONIC PIT-) I+)Y
I(-I RX
LH LH PRL
ION . (
(-I GONADAL GONAD
LH RECEPTOR !
DOWN REGULATION%
GONAD-______. 'k #
I-I
o4STEROIDOGENESIS j
AAAAAAADVIDPCTAPTT.
I
I
I
I
I
I
IVIAVIINlf KT/rmu.3 tA c -o. a
TUMOR u.-
INHIBITION
(-I= INHIBITION
+) STIMULATION
FIG. 9. Possible
mechanisms of action
of LHRH agonists on
tumor regression.
DESENSITIZATI
40 ALAN CORBIN
?
IANTITUMOR EFFECTS OF LHRH ANALOGUES -A REVIEW
OVERVIEW
The animal studies reviewed unequivocally demonstrate the antireproductive and
antitumor properties of the LHRH analogues providing justification for a detailed
evaluation in selected oncologic settings. The limited clinical investigations de-
scribed confirm the basic "medical castration" effects in patients with selected
reproductive organ tumors that consistently and predictably have been observed in
the preclinical studies.
The mechanisms by which the LHRH analogues inhibit tumor growth may be
numerous. The major mechanism ofthe agonists appears to be viapituitary-gonadal
downregulation and desensitization: the LHRH agonist induces initial gonadotropin
hypersecretion that leads to gonadal gonadotropin receptor loss and reduced
steroidogenesis; continuous agonist administration results in hypophysial desen-
sitization and LHRH receptor downregulation leading to blunted secretion and
decreased blood levels of gonadotropins producing a further suppression of
steroidogenesis and removal ofsteroid support for the tumor. Additionally, the shift
in steroidogenic patterns due to interference with the enzymes responsible for
precursor conversion may lead to a decrease or an increase of a particular steroid
(e.g., excess progesterone in the male).
The reduced serum levels of gonadotropins, prolactin, and the androgenic and
estrogenic steroids are representative of "selective hypophysectomy" or of castration,
procedures that can be effective in arresting the growth of particular tumors.
Moreover, the agonist may have effects directly on the gonad since the testes and
ovaries have been shown to possess LHRH receptors [16], or directly on the tumor
itself (e.g., prostate), although there are conflicting data supporting the presence of
LHRH receptors in secondary sex organs.
Of interest, however, is the report of Sundaram et al. [56] demonstrating that
LHRH agonists could block the stimulatory effect of exogenous sex steroids on ac-
cessory reproductive organs in castrated and/or hypophysectomized male and
female rats. These results suggested that the analogue could directly antagonize the
effect of sex steroids at the target organ level.
Preliminary data on the LHRH antagonists indicate that these LHRH derivatives
can also inhibit tumor growth. The mechanism ofthe LHRH antagonistsis via com-
petitive inhibition of pituitary LHRH receptors, preventing endogenous LHRH
stimulation of pituitary gonadotrophs and gonadotropin secretion, subsequently
leading to depressed gonadal steroidogenesis.
Several questions arise regarding the nature of the tumor that would be suscepti-
ble to LHRH analogue intervention, the dosing regimens, whether these peptides are
to be administered solely or as adjuncts to established therapies, and routes of ad-
ministration. The presence ofhigh concentrations ofgonadal steroid receptors (and
perhaps even those for prolactin) in various neoplasias (e.g., estrogen receptor-
positive) is used as a marker to judge if a tumor is a candidate for antihormone
therapy [26]. In numerous instances, tumors are composed of heterogeneous cell
populations, each subset possessing different physiologic properties, and varied
metastatic potential and susceptibility to various modes of therapy [57]. Receptors
for estrogen, androgen, and progestagen have been found in tumors ofreproductive
origin (e.g., mammary, endometrial, ovarian, prostatic); the presence of all or of
some of these receptors in primary and metastatic tumor tissue has been utilized to
determine ifantihormone therapy would be appropriate. Tumor receptor concentra-
tions may not only dictate the nature of the treatment but they can be of prognostic
41value in terms of recurrence and survival, especially with regard to the presence of
estrogen receptors in breast and endometrial carcinomas [27,58-61]. However, it
should be realized that only approximately 50 percent of breast cancers that are
deemed estrogen receptor positive respond to ablative or endocrine therapy; this
perplexity complicates the view that an ER+ tumor condition can be clearly related
to not only the hormonal factors that are supporting the tumor but also to its pro-
jected management [61a].
Non-reproductive organ tumors (e.g., renal cell carcinoma) or ectopic tumors
(e.g., chorionic gonadotropin-secreting lung carcinoma), which may possess
gonadal steroid receptors, also may benefit from antihormone/LHRH analogue
therapy [62-64].
The possibility that the LHRH agonists may act directly on the tumor (i.e., ex-
tragonadal reproductive tissue) remains an intriguing proposition [16]. The in vitro
study of Meyskens et al. [65] revealed that human melanoma tumor stem cells can
specifically bind LH and that the gonadotropin also could suppress cell growth.
These authors suggested that LH may modulate the growth of human melanoma
cells and that control of LH levels may have clinical utility in this disease. Con-
ceivably, LHRH agonists, per se, may have direct antitumor effects, by substituting
for LH [16] and also by virtue of their ability to cause LH release under carefully
controlled chronic regimens (i.e., pulsatile delivery in treatment of hypogonado-
tropic hypogonadal disorders), they may be of therapeutic value in a broader range
of neoplastic diseases. However, the role of LH in breast cancer is unknown.
Zumoff et al. [65a] have proposed that subnormal LH levels and its abnormal diur-
nal patterns may be associated with increased risk of breast cancer, subserved by
hypothalamic dysfunction.
Limited clinical information exists on dosing regimens, use as adjunctive therapy,
and routes of administration. However, it would appear from the available animal
and human experiences that continuous treatment with the LHRH analogues would
be required to maintain a condition of tumor abeyance; the animal investigations
clearly indicate that interruption of treatment will lead to tumor recrudescence.
Since antisteroidal and LHRH agonist interventions are not cytotoxic (i.e., tumor-
cidal), other traditional approaches (surgery, radiation, chemotherapy) might be re-
quired; the LHRH analogue would play an adjunctive, palliative role, perhaps
minimizing the requirements for and the toxic side effects of radiation or
chemotherapy, retarding metastases, or reducing tumor size to provide more
favorable conditions for surgery.
The possibility that the LHRH agonists may provide a "sparing" effect on chemo-
therapeutic requirements and/or their damaging side effects has been suggested by
Glode et al. [66]. Alkylating antineoplastic agents such as cyclophosphamide
(Cytoxan) cause severe damage to the rapidly dividing germinal epithelium of the
gonads [66a]. In order to reduce the sensitivity of these highly proliferative cells to
the deleterious effects of the chemotherapeutic agent, the pituitary-testicular axis of
mice was suppressed by chronic administration with Leuprolide. While Cytoxan
alone produced tubular and epithelial disorganization and disrupted morphology,
the addition ofthe LHRH agonist protected against these effects. Interestingly, mice
treated with only the Leuprolide showed normal testicular cytoarchitecture. It has
been reported that the male mouse is highly resistant to the antireproductive effects
of LHRH agonists [67] at doses in considerable excess of those producing rapid and
dramatic disruption of reproductive processes in the rat [1,32,33]. The mechanism
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by which the agonist protects spermatogenesis at the level of the seminiferous tubule
against the damaging effects of the cytotoxic agent is not certain; such effects may
be manifested indirectly via gonadotropin suppression with low doses of the agonist,
sparing germinal cell function, or directly on the testis itself. However, it should be
noted that any extra-pituitary, direct testicular effect could be exerted only through
the Leydig cells, since this is the only compartment possessing detectable LHRH
receptors [68]. Irrespective of these confounding factors, the study of Glode et al.
[66] suggests the potential ancillary antitumor use of LHRH agonists.
It has been proposed by Auclair et al. [37] that native LHRH could be used for
benign prostatic hyperplasia, since LHRH has minimal and therefore less
disruptive consequences on testicular tissue. On the other hand, the potent LHRH
agonists would be employed, because of their more rapid, prominent, and pro-
tracted desensitizing and downregulatory effects on the pituitary-gonadal axis, for
the more fulminating neoplasias (prostatic and breast carcinoma) where a "phar-
macologic castration" would be desired.
The present modes of clinical administration include subcutaneous and nasal
spray delivery. Although the LHRH agonists have been shown to be orally active,
the large doses that would be required are impractical. In fact, some of the sub-
cutaneous doses that have been used in the human breast and prostatic cancer
studies are in the milligram range; even at these relatively high doses, the human
mammary carcinoma trials, in contrast to the prostate studies, have not been en-
couraging. The nasal spray approach appears to be a reasonable alternative to tradi-
tional parenteral dosing methods, having a high degree of patient compliance that
has been demonstrated in long-term clinical contraceptive evaluation of these pep-
tides [1]. Another suggested mode of delivery is the transdermal one akin to that
used for medicating angina patients with nitroglycerin.
CONCLUSIONS
The antifertility properties of the LHRH analogues provide a novel approach to
hormonotherapy of cancer. The LHRH agonists and the antagonists can disrupt
pituitary-gonadal function and suppress steroidogenesis, resulting in removal of
support for gonadal steroid-dependent reproductive structures. The collective
animal and clinical data support the contention that these compounds (particularly
the LHRH agonists) may be useful drugs for the treatment of gonadal-steroid de-
pendent tumors or as therapeutic adjuncts to traditional procedures including
surgical extirpation, chemotherapy, radiation, and antigonadal steroidal medication
by an effect that is tantamount to a "pharmacologic castration."
The LHRH agonists may be of restricted therapeutic value in those cases of breast
tumors that are overtly estrogen receptor-positive. By analogy, a similar view might
apply to the treatment of prostatic tumors that would require an androgen (and/or
estrogen) receptor-positive dimension [69-71]. However, neoplasias of a general
reproductive target category, possessing additional receptors for prolactin, pro-
gesterone, LH, and LH-like hormones (e.g., HCG), may be responsive candidates
for LHRH agonist intervention. Furthermore, because of the heterogeneous nature
oftumor cell populations, non-reproductive neoplasias also possessing the above ar-
ray of receptors may be likely candidates.
Finally, the role of growth hormone (GH) in supporting tumor growth should be
noted. It has been suggested that elimination of prolactin and GH (because the latter
is both growth-promoting and lactogenic and binds to prolactin receptors) may have
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therapeutic utility in breast cancer [31,31c,72]. To this end, a combination of an
LHRH agonist plus somatostatin (or an analogue) might be employed to produce a
"medical hypophysectomy," simultaneously suppressing the secretion of
gonadotropins, prolactin, gonadal steroids and growth hormone (DP Rose, per-
sonal communication).
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